<DOC>
<DOCNO>
EP-0003682
</DOCNO>
<TEXT>
<DATE>
19790822
</DATE>
<IPC-CLASSIFICATIONS>
A61K-31/60 A61K-47/48 A61K-9/08 <main>A61K-9/08</main> 
</IPC-CLASSIFICATIONS>
<TITLE>
process for solubilizing an insoluble drug and an aqueous solution prepared by this process.
</TITLE>
<APPLICANT>
merck & co incus<sep>merck & co. inc.<sep>merck &amp; co., inc.126, east lincoln avenue p.o. box 2000rahway new jersey 07065-0900us<sep>merck & co. inc. <sep>
</APPLICANT>
<INVENTOR>
lo pak-kan albert<sep>williams james bown<sep>lo, pak-kan albert<sep>williams, james bown<sep>lo, pak-kan albert17 lombardi streetedison, new jersey 80017us<sep>williams, james bown4 coventry drivefreehold new jersey 07728us<sep>lo, pak-kan albert <sep>williams, james bown  <sep>lo, pak-kan albert17 lombardi streetedison, new jersey 80017us<sep>williams, james bown4 coventry drivefreehold new jersey 07728us<sep>
</INVENTOR>
<ABSTRACT>
a soluble complex of an insoluble drug, exemplified  by rafoxanide, is formed with polyvinylpyrrolidone and  water.  the complex is formed by combining the insoluble  drug and polyvinylpyrrolidone in a suitable water-miscible  organic solvent, preferably acetone or glycerolformal,  and water.  the complex is formed in situ.  the  solvent may be removed, if desired, and the complex  remains in aqueous solution.  the aqueous solution is  then suitable for injection and may be used to treat fasciola  or liver fluke infections.  
</ABSTRACT>
</TEXT>
</DOC>
